ArticleJournal of gastroenterology2014
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
Article in Journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Pooled it
- Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Journal of gastroenterology · 2017Pooled it
- Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2016Pooled it
- The Association Between Phenotypic Age and Primary Loss of Response to Biologic Agent in Patients with Crohn's Disease.Journal of inflammation research · 2025Article
- Evaluation of the clinical utility of measuring serum infliximab and vedolizumab concentrations during monitoring of biologic therapy in patients with inflammatory bowel disease.Przeglad gastroenterologiczny · 2025Article
- A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease.Annals of medicine · 2023Article
- A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy.Journal of clinical medicine · 2023Review
- Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor-α antibodies.Intestinal research · 2022Article
- Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis.ACG case reports journal · 2022Article
- Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.Scientific reports · 2020Article
- Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2019Article
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Article
- Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.Digestive diseases and sciences · 2018Article
- Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.Pharmaceutical research · 2017Review
- Observational
- New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.Inflammatory bowel diseases · 2016Review
- Article
- Disease monitoring in inflammatory bowel disease.World journal of gastroenterology · 2015Review
- Therapeutic drug monitoring in patients with inflammatory bowel disease.World journal of gastroenterology · 2014Review
- Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ability of serum infliximab level to predict clinical outcome in infliximab therapy in Crohn's disease is unclear. Here, we aimed to clarify the correlation between the timing of loss of response (LOR) to treatment and a decrease in serum infliximab level, and, in addition, to identify an indicator of infliximab level.
methodsThe study used data from a previous clinical study of infliximab for Crohn's disease, in which infliximab was initially given at 0, 2, 6 weeks at 5 mg/kg, and then at 8-week intervals to 62 week-10 responders. Of these 62, here we analysed data from 57 in whom Crohn's disease activity index and serum infliximab level were evaluated at week 14.
resultsTwelve patients showed a clinical response despite an infliximab level <1 μg/mL at week 14; of these, 8 (67 %) experienced LOR by week 54. A decrease in infliximab level preceded LOR in 6 (75 %). In receiver operating characteristic curve analysis, C-reactive protein (CRP) showed better performance in detecting an infliximab level <1 μg/mL. Infliximab level was <1 μg/mL in 60-80 % of patients with CRP >0.5 mg/dL. Time to LOR (median: 22.0 weeks) was significantly longer than that to a decrease in infliximab level to <1 μg/mL (14.0 weeks, p < 0.05) or to an increase in CRP to >0.5 mg/dL (14.0 weeks, p < 0.01).
conclusionsA decrease in serum infliximab level preceded LOR, and was easily detected by an increase in CRP. The CRP may be an indicator of serum infliximab level in predicting LOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.